These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38576411)

  • 1. TERT Promoter Mutations Increase Tumor Aggressiveness by Altering TERT mRNA Splicing in Papillary Thyroid Carcinoma.
    Sako A; Matsuse M; Saenko V; Tanaka A; Otsubo R; Morita M; Kuba S; Nishihara E; Suzuki K; Ogi T; Kawakami A; Mitsutake N
    J Clin Endocrinol Metab; 2024 Sep; 109(10):e1827-e1838. PubMed ID: 38576411
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Tanaka A; Matsuse M; Saenko V; Nakao T; Yamanouchi K; Sakimura C; Yano H; Nishihara E; Hirokawa M; Suzuki K; Miyauchi A; Eguchi S; Yoshiura KI; Yamashita S; Nagayasu T; Mitsutake N
    Thyroid; 2019 Aug; 29(8):1105-1114. PubMed ID: 31286848
    [No Abstract]   [Full Text] [Related]  

  • 3. Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer.
    Song YS; Yoo SK; Kim HH; Jung G; Oh AR; Cha JY; Kim SJ; Cho SW; Lee KE; Seo JS; Park YJ
    Endocr Relat Cancer; 2019 Jun; 26(6):629-641. PubMed ID: 30999281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Expression Profiles of AHNAK2, DCSTAMP, FN1, and TERT Correlate With Mutational Status and Recurrence in Papillary Thyroid Carcinoma.
    Staubitz-Vernazza JI; Müller C; Heymans A; Nedwed AS; Schindeldecker M; Hartmann M; Kloth M; Schad A; Roth W; Musholt TJ; Hartmann N
    Genes Chromosomes Cancer; 2024 Aug; 63(8):e23256. PubMed ID: 39193983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological indicators for TERT promoter mutation in papillary thyroid carcinoma.
    Na HY; Yu HW; Kim W; Moon JH; Ahn CH; Choi SI; Kim YK; Choi JY; Park SY
    Clin Endocrinol (Oxf); 2022 Jul; 97(1):106-115. PubMed ID: 35343605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
    Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M
    J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
    Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
    Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
    Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O
    Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer.
    Bu R; Siraj AK; Divya SP; Kong Y; Parvathareddy SK; Al-Rasheed M; Al-Obaisi KAS; Victoria IG; Al-Sobhi SS; Al-Dawish M; Al-Dayel F; Al-Kuraya KS
    Int J Cancer; 2018 May; 142(10):2028-2039. PubMed ID: 29266240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct transcriptional and prognostic impacts of TERT promoter mutations C228T and C250T in papillary thyroid carcinoma.
    Marczyk VR; Maia AL; Goemann IM
    Endocr Relat Cancer; 2024 Sep; 31(9):. PubMed ID: 38973620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.
    Gandolfi G; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A; Sancisi V
    Eur J Endocrinol; 2015 Apr; 172(4):403-13. PubMed ID: 25583906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid Cancer.
    Trybek T; Walczyk A; Gąsior-Perczak D; Pałyga I; Mikina E; Kowalik A; Hińcza K; Kopczyński J; Chrapek M; Góźdź S; Kowalska A
    Endocrinology; 2019 Oct; 160(10):2328-2338. PubMed ID: 31305897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
    Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
    Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation.
    Chien MN; Yang PS; Hsu YC; Liu TP; Lee JJ; Cheng SP
    Head Neck; 2018 Nov; 40(11):2528-2537. PubMed ID: 30102829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of Papillary Thyroid Carcinoma to Anaplastic Carcinoma in Metastatic Lymph Nodes: Solid/Insular Growth and Hobnail Cell Change in Lymph Nodes Are Predictors of Subsequent Anaplastic Transformation.
    Odate T; Oishi N; Kawai M; Tahara I; Mochizuki K; Akaishi J; Ito K; Katoh R; Kondo T
    Endocr Pathol; 2021 Sep; 32(3):347-356. PubMed ID: 33761111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis.
    Vuong HG; Altibi AMA; Duong UNP; Hassell L
    Clin Endocrinol (Oxf); 2017 Nov; 87(5):411-417. PubMed ID: 28666074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer.
    Myung JK; Kwak BK; Lim JA; Lee MC; Kim MJ
    Cancer Res Treat; 2016 Jul; 48(3):942-7. PubMed ID: 26727717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coexistence of
    Rusinek D; Pfeifer A; Krajewska J; Oczko-Wojciechowska M; Handkiewicz-Junak D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Cyplinska R; Zembala-Nozynska E; Chekan M; Chmielik E; Kropinska A; Lamch R; Jurecka-Lubieniecka B; Jarzab B; Czarniecka A
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30200646
    [No Abstract]   [Full Text] [Related]  

  • 19. BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients.
    Sun J; Zhang J; Lu J; Gao J; Ren X; Teng L; Duan H; Lin Y; Li X; Zhang B; Liang Z
    PLoS One; 2016; 11(4):e0153319. PubMed ID: 27064992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression.
    Yuan X; Mu N; Wang N; Strååt K; Sofiadis A; Guo Y; Stenman A; Li K; Cheng G; Zhang L; Kong F; Ekblad L; Wennerberg J; Nilsson IL; Juhlin CC; Larsson C; Xu D
    Oncogene; 2019 Feb; 38(7):965-979. PubMed ID: 30181547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.